Medicare\u27s Chronic Care Improvement Pilot Program: What Is Its Potential? by Super, Nora
NHPF Issue Brief
No.797 / May 10, 2004
Medicare’s Chronic Care
Improvement Pilot Program:
What Is Its Potential?
Nora Super, Principal Research Associate
OVERVIEW — This paper describes the voluntary chronic care improvement
program under traditional fee-for-service Medicare as authorized by the Medi-
care Prescription Drug, Improvement, and Modernization Act (MMA) of 2003
(Public Law 108-173; section 721). This brief analyzes the emerging issues
raised by this new program, including which chronic conditions and regional
areas will be targeted, the types of entities that may participate, the physician’s
role in care management, and the adoption and use of health information tech-
nology and evidence-based clinical guidelines.
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INTRODUCTION
The new Medicare law puts into motion sweeping changes to the nearly
40-year-old program, from instituting a new prescription drug benefit
to redesigning and renaming Medicare+Choice to become Medicare Ad-
vantage. Among its many far-reaching provisions, the law also aims to
improve chronic care for Medicare beneficiaries by establishing several
new programs and demonstration projects.
Chronic care improvement can be, and is, defined in many ways through-
out the Medicare Prescription Drug, Improvement, and Modernization Act
(MMA) of 2003 (Public Law 108-173). For example, the law requires the
Department of Health and Human Services (DHHS) to
develop a research and demonstration plan focused on chronically ill ben-
eficiaries.1 Its “medication therapy management” provisions require pre-
scription drug plans to ensure that Medicare beneficiaries with multiple
chronic diseases are taking their prescribed drugs appropriately.2 Other
provisions establish pay-for-performance demonstration programs that will
reward physicians for promoting continuity of care and managing chronic
conditions according to evidence-based clinical guidelines.3
Perhaps most significantly, section 721 of the MMA adds a new section
1807 to the Social Security Act to establish a large-scale, chronic care
improvement program. The new program promises to be far broader in
nature than traditional demonstration projects. It is targeted at beneficia-
ries enrolled in fee-for-service (FFS) Medicare, which finances health care
for nearly 90 percent of Medicare beneficiaries. The new program defines a
new contracting entity that will be expected to achieve financial as well as
clinical results. Moreover, the program will be rigorously tested with the
use of randomized controlled trials to evaluate its effectiveness.
On April 23, 2004, the Centers for Medicare and Medicaid Services (CMS)
published a request for proposals (RFP) outlining specifications for poten-
tial contractors.4 Though the RFP provides many details about how CMS
intends to run the program, several key policy issues still remain unan-
swered. For example, what kinds of entities can reasonably be considered
a “chronic care improvement organization”? What is the physician’s role
in care management? How flexible is the program design? The initial phase
of the program is required by statute to be up and running by December
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2004; applications from potential program contractors must be received
by August 6, 2004. Thus, there is a sense of urgency for broader under-
standing and sharper clarification of some key details. This issue brief
summarizes the major provisions of the program and the related RFP
and considers key questions that have emerged.
PURPOSE
As reported by the Institute of Medicine (IOM), a huge chasm exists be-
tween best medical practices that follow evidence-based treatment guide-
lines and the care many patients—especially those with chronic condi-
tions—actually receive.5 A multispecialty expert physician study found
that, during a three-year period, Medicare beneficiaries received certain
recommended services less than two-thirds of the time for conditions with
a high prevalence among the elderly population (such as heart disease,
diabetes, breast cancer, and stroke).6 More than half of all Medicare ben-
eficiaries with chronic obstructive pulmonary disease (COPD) were hos-
pitalized for what was considered an avoidable respiratory diagnosis.
Vulnerable populations, such as African Americans and residents in ar-
eas of poverty with shortages of health care professionals, were even less
likely to receive necessary care than their counterparts.
The implications for the care and cost of Medicare beneficiaries are stag-
gering. Nearly 80 percent of Medicare beneficiaries have at least one of
the following chronic conditions: stroke, diabetes, emphysema, heart dis-
ease, hypertension, arthritis, osteoporosis, Parkinson’s disease, or urinary
incontinence.7 Several of these chronic conditions are associated with much
higher spending in the Medicare program. The costliest 5 percent of Medi-
care beneficiaries account for about half of all Medicare spending each
year. Among this top 5 percent, 47 percent had congestive heart failure
(CHF) and 35 percent had diabetes.8
Beneficiaries with chronic conditions are more likely to experience prob-
lems with care coordination because they often receive care from a vari-
ety of physicians and specialists. They also typically require multiple
prescriptions, which increases the likelihood of adverse drug interac-
tions and errors, and they are more likely to be subjected to multiple
tests or procedures.9 These beneficiaries are at greater risk of being ad-
mitted to the hospital or of visiting emergency rooms for preventable
conditions or complications.
Based on a belief that encouraging adherence to evidence-based treat-
ment guidelines will reduce spending and achieve better health out-
comes, lawmakers, led by Rep. Nancy Johnson (R-CT), devoted subtitle
C of Title VII of the new Medicare law to chronic care improvement.
Section 721 provides the most comprehensive, far-reaching approach
toward reaching this goal.
Those with chronic
conditions are more
likely to experience
care coordination prob-
lems because they of-
ten receive care from a
variety of physicians
and specialists.
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MAJOR FEATURES
The new chronic care improvement pilot program has three major features:
■ Population-based—Modeled on extant disease management (DM)
programs, CMS will identify, in advance, beneficiaries who might benefit
from intervention. This population-based strategy is a departure from
most current practices in Medicare. Eligible patients will be identified
before program implementation rather than on the basis of referrals from
physicians and other providers. Program contractors will be held ac-
countable for the health outcomes and utilization of all members of the
targeted group, not just those beneficiaries who choose to participate.
Program contractors will be given historical claims data on their assigned
targeted beneficiaries and be permitted to do proactive outreach.
■ Large-scale—The program is intended to be broad in scope and
scale. Faced with multiple competing demands, CMS officials have
indicated that the programs must be conducted on a large enough
scale that they can be effectively managed at the federal level and that
evaluation results will be statistically significant. As described in the
RFP, CMS wants to test strategies that are “scalable, replicable, and
adaptable nationally.”10
The law requires that the program be offered in geographic areas in which
at least 10 percent of the FFS Medicare population, in aggregate, resides.
In the RFP, CMS indicates there will be approximately 10 pilot projects in
different regions of the country, with each serving about 15,000 to 30,000
beneficiaries over a three-year period. The DHHS secretary will prospec-
tively identify program participants as well as a comparable control group
in each geographic area. These requirements indicate that the region will
have to be geographically large or heavily populated.
■ Demonstrated Effectiveness—Throughout the legislative language, a
strong emphasis is placed on evaluation and achievement of specified
targets. DHHS is required to contract with an independent evaluator to
monitor the chronic care improvement (CCI) programs, and the pro-
grams themselves are also required to provide CMS with progress
reports. CMS will have to report regularly to Congress on the status of
the pilots and of the whole program.
For evaluation purposes, the MMA requires that targeted beneficiaries be
randomly assigned to an intervention or a control group. Because the
program is voluntary, the intervention group will include beneficiaries
who choose to participate in the program as well as those who refuse.
The evaluation must assess the following factors:11
■ Quality improvement measures, such as adherence to evidence-based
guidelines and re-hospitalization rates.
■ Beneficiary and provider satisfaction.
■ Health outcomes.
■ Financial outcomes, including any cost savings to the program.
The MMA requires that
targeted beneficiaries
be randomly assigned
to an intervention or a
control group.
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KEY ELEMENTS
Targeted Beneficiaries
The legislation is designed to reach beneficiaries who have one or more
“threshold” chronic conditions. The RFP specifies that the pilot program
will focus on CHF, complex diabetes, and, in some cases, COPD.12
To be eligible to participate, beneficiaries must be entitled to benefits under
Part A and enrolled in Part B, but not enrolled in a plan under Part C (Medi-
care Advantage). CMS has developed a method of identifying targeted
beneficiaries who may benefit from participation in a CCI program.13 CMS
will initially contact the beneficiaries to let them know of their eligibility.
The program is completely voluntary; beneficiaries who refuse to partici-
pate will not be contacted by CCI organizations offering services or for
other reasons. Beneficiaries also may terminate participation at any time.
Programs will be available at no charge to the beneficiary.
Care Management Plans
CCI programs are required to develop an individualized, goal-oriented,
care management plan in consultation with each targeted beneficiary. The
plan must include the following (to the extent appropriate):14
■ A designated point of contact responsible for communications with the
beneficiary and for facilitating communications with other health care provid-
ers under the plan.
■ Self-care education for the beneficiary (through approaches such as disease
management or medical nutrition therapy) and education for primary caregivers
and family members.
■ Education for physicians and other providers as well as collaboration to
enhance communication of relevant clinical information.
■ The use of monitoring technologies that enable patient guidance through the
exchange of pertinent clinical information, such as vital signs, symptomatic
information, and health self-assessment.
■ The provision of information about hospice care, pain and palliative care, and
end-of-life care.
CCI Program Responsibilities and
Performance Risk Requirements
In addition to providing and carrying out care management plans for
program participants, CCI programs must “use decision-support tools
such as evidence-based practice guidelines...[and] develop a clinical in-
formation database to track and monitor each participant across settings
and to evaluate outcomes.”15
The program is com-
pletely voluntary.
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In an effort to provide contractors financial incentives to achieve clinical
and financial goals, the CCI program’s fees will be at risk, based on perfor-
mance.16 CCI programs will be paid on a per-member–per-month basis for
all beneficiaries who confirm participation. These fees will be separate from
and in addition to basic Part A and Part B payments. CCI programs will
not be responsible for beneficiary medical costs. Their fees will be consid-
ered a Medicare administrative fee.
The RFP specifies that contractors will be required to save the program a
minimum of 5 percent of health care costs, net of the program’s fees. Con-
tractors will be at risk for all of their fees if the total Medicare claims
payments in their targeted population are not at least 5 percent less than
what CMS estimates would have been spent on the population had the
services not been provided, compared with the control group. The target
population’s total expenditures will include those who refused to partici-
pate or dropped out. The contractors may also have to refund some or all
of their fees if they do not meet agreed-on standards for improvements in
the quality of care and patient satisfaction levels among enrollees.
Phased-In Implementation
The legislation calls for two distinct phases of implementation. Under
Phase I, CMS and CCI programs will enter into agreements lasting for a
three-year period. During this period, CMS is required to test and evalu-
ate the CCI programs using randomized controlled trials. If independent
evaluations find that a program has met certain conditions, including
improving the clinical quality of care, improving beneficiary satisfaction,
and achieving targets for savings, then that program or components of
that program can be expanded to Phase II without further congressional
authorization. Phase II cannot begin earlier than two years after the imple-
mentation of the initial program or later than six months after the
completion of the program. Under Phase II, the secretary must expand
the implementation of the program to other geographic areas, which may
include expansion on a national basis.
KEY QUESTIONS
The CCI program offers an important opportunity to improve the care
of chronically ill beneficiaries enrolled in FFS Medicare. Moreover, if
the programs are rigorously tested, they can provide evidence about
the cost-effectiveness of certain interventions.
As CMS prepares to launch this program, stakeholders have raised a num-
ber of key questions ranging from the practical to the rhetorical. Some have
been answered by the RFP, such as which conditions will be targeted and
how regions will be selected. Other questions, relating to how well these
strategies work for the elderly, the role of physicians, and how CCI pro-
grams will be integrated with prescription drug benefits, will have to be
tested in the field.
The RFP specifies that
contractors will be
required to save the
program a minimum
of 5 percent of health
care costs, net of the
program’s fees.
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Which Conditions Will Be Targeted?
The legislation requires that one or more “threshold” conditions be
present for beneficiaries to be eligible. Lawmakers decided not to limit
eligibility to only those with multiple conditions. The legislation does
require each program to have a process with which to screen each tar-
geted beneficiary “for conditions other than threshold conditions, such
as impaired cognitive ability and co-morbidities.”17
The question of which conditions to target was carefully considered by
CMS. The legislation suggests targeting diabetes, CHF, or COPD but does
not mandate it. Mindful of the three-year evaluation period, CMS seems to
have been persuaded by arguments that they should target conditions most
likely to achieve short-term results. The RFP specifies that the initial pro-
grams should be designed for beneficiaries with CHF and/or diabetes with
significant co-morbidities (that is, complex diabetes). In one or two regions,
a program may address COPD.
CHF and diabetes are among the five most common chronic diseases in
the Medicare population. In a Health Affairs article, Sandra Foote argues
that “[o]ne of the most important design decisions for FFS Medicare
demonstrations is to select target populations that seem likely to ben-
efit from the types of interventions to be tested.”18 Beneficiaries with
CHF, for example, represent only 14 percent of Medicare beneficiaries,
but they account for 43 percent of Medicare expenditures (Table 1).19
The potential for savings to the Medicare program is enormous. Ac-
cording to the Agency for Healthcare Research and Quality (AHRQ),
nearly 800,000 Medicare beneficiaries with CHF had hospital admis-
sions in 1999 that could have been avoided through better outpatient
management of their conditions.20
In the RFP, CMS says it chose CHF and/or complex diabetes or COPD,
“because they are major population subgroups within Medicare with sig-
nificant health risks and disproportionately high health care costs that
are not being consistently managed.”21 Moreover, CMS has explicitly de-
cided to target those beneficiaries at greatest risk. To assess risk, CMS
will focus on beneficiaries who have moderate to high Hierarchical Coex-
isting Condition (HCC) risk adjustment scores “in order to achieve our
clinical and financial objectives within the 3-year program window.”22
This emphasis on short-term return on investment (ROI) may have pre-
cluded CMS from selecting as thresholds those conditions with a longer
projected ROI, such as arthritis or depression. CMS maintains that they
chose to focus on two or three conditions to simplify the evaluation and
to allow comparisons between the sites. Nonetheless, agency officials
recognize that other conditions are amenable to chronic care improve-
ment interventions. Moreover, CMS will expect CCI organizations to
manage all of a beneficiary’s conditions, according to officials.
CMS seems to have
been persuaded that
they should target
conditions most likely
to achieve short-term
results.
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Will Disease Management
Work for Medicare Beneficiaries?
The structure of the program suggests a strong bias toward disease man-
agement (DM) models currently in operation today. DM programs have
proliferated in the private sector since the early 1990s. Pharmaceutical com-
panies created the early programs, which were aimed at increasing patients’
compliance with drug regimens.23 Today’s programs typically target indi-
viduals with specific diseases (for example, asthma, diabetes, CHF) who
are covered by commercial insurance, Medicaid, or Medicare Advantage.
DM programs generally provide physicians with evidence-based practice
guidelines and promote patient self-management through education. More
recently, DM programs have reportedly evolved to manage multiple chronic
conditions. Nearly half of all states have implemented or are in the process
of implementing Medicaid disease management programs.24 However,
Medicaid beneficiaries who are concurrently eligible for Medicare (so-called
“dual eligibles”) are almost always excluded.25
Beneficiary advocates and some physician groups have raised concerns
about whether or not these programs can be modified to effectively treat
the Medicare population. Elderly and disabled people tend to have mul-
tiple chronic conditions. Nearly 80 percent of Medicare beneficiaries have
at least one chronic condition, while more than 60 percent have two or
TABLE 1
Medicare Outlays for Beneficiaries with Diabetes or Congestive Heart Failure,
among Noninstitutionalized, Non-HMO Members Only, 1999
Percent of FFS Medicare Percent of FFS Percent of Total
No. of Beneficiaries Outlays per Year Medicare Outlays FFS Medicare
Beneficiaries by Subgroup (in billions) by Subgroup Outlays
Not Medicaid-Eligible
Congestive Heart Failure 3,113,151 13% $47.9 42% 34%
Diabetes 4,050,361 17 $34.3 30 24
All Non-Medicaid 23,732,291 100 $112.8 100 80
Medicaid-Eligible
Congestive Heart Failure 749,265 19 $13.0 47 9
Diabetes 1,028,770 25 $10.8 39 8
All Non-Medicaid 4,040,034 100 $27.8 100 20
All FFS Medicare
Congestive Heart Failure 3,862,416 14 $60.9 43
Diabetes 5,079,131 18 $45.1 32
All 27,772,326 100 $140.6 100
Source:  Sandra M. Foote, “Population-Based Disease Management under Fee-For-Service Medicare, Health Affairs, 22, no. 4 (July/August 2003); based on
Medicare Current Beneficiary Survey Cost and Use files, 1999.
Notes: Expenditures shown are for all Medicare outlays, not limited to congestive heart failure (CHF) or diabetes treatment. Beneficiaries with any diagnosis
of diabetes or CHF in a physician office visit were counted. Beneficiaries with CHF and diabetes appear in both categories. HMO = health maintenance
organization. FFS = fee-for-service.
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more. Of this group with two more conditions, almost
one-third (20 percent of the total Medicare popula-
tion) has five or more chronic conditions or co-mor-
bidities (Figure 1).26 Fewer clinical guidelines exist for
treatment of beneficiaries with multiple chronic con-
ditions, making the identification of the “evidence-
based” care more difficult.
Patient self-management is a key component of
most commercial DM programs.27 Medicare benefi-
ciaries are more likely to be poor, frail, and
cognitively impaired than enrollees of commercial
plans. Geriatricians have argued that self-manage-
ment and patient education techniques simply do
not work for persons with Alzheimer’s disease or a
related dementia.28 On the other hand, at the press
conference announcing the RFP, Rep. Nancy
Johnson argued passionately that caregivers of in-
dividuals with dementia could find these CCI pro-
grams tremendously helpful.
Robert Berenson and Jane Horvath have cautioned
that the DM approach “is likely to be of limited ben-
efit to a significant portion of beneficiaries who have
complex chronic care needs.”29 These patients often
are treated by multiple physicians and have compli-
cated drug regimens. Care coordination or intensive
case management may be more appropriate. Care coordination services
can include multidisciplinary care conferences and coordination of clinical
care across multiple providers.30 Case management typically focuses on
the individual health care needs of high-risk patients with multiple or com-
plex medical conditions, who may be at increased risk for hospitalizations.31
Noting these concerns, the RFP does require applicants to “describe
strategies for supporting participants with more intensive needs,”32 as a
consideration in the selection process. Nothing prevents CCI programs from
including care coordination and intensive case management in their array
of services. Moreover, CMS notes that DM programs have not been rigor-
ously tested with large populations of people aged 65 or older or with
severely disabling conditions in a fee-for-service context. The pilot
program provides an opportunity to do so.
What Types of Organizations Can Implement CCI Programs?
The legislation specifies that CCI programs may be implemented through
a “disease management organization, health insurer, integrated delivery
system, physician group practice, a consortium of such entities, or any
other legal entity that the Secretary determines appropriate to carry out a
chronic care improvement program.”33 The RFP repeats this list of
FIGURE 1
Percentage of Medicare Beneficiaries
with Varying Numbers of Chronic Conditions,
1999
Source: Gerard Anderson, Johns Hopkins University, testimony before the
Subcommittee on Health, Committee on Ways and Means, U.S. House of
Representatives, April 16, 2003.
Three – 14.8% Two – 16.3%
One – 15.1%
None – 22.1%Five or more – 20.3%
Four – 11.3%
10
NHPF Issue Brief No.797 / May 10, 2004
eligible organizations. CMS officials insist they will wait to see what the
market brings, rather than define the organizations in advance. The RFP
purposefully does not require applicants to be accredited as DM organi-
zations “in the interest of encouraging proposals from a broad array of
organizational models.”34
Nonetheless, the scope and size of the program suggest that organiza-
tions that operate in large markets with population-based models are
most likely to be chosen. Large health plans and DM organizations that
already provide some chronic care services seem best positioned to meet
the program criteria. The contracted CCI programs will need a health
data analysis infrastructure (including clinical information, financial sys-
tems, performance monitoring) as well as program experience (staff,
clinical protocols, relationships with local providers and community or-
ganizations). They will also have to have the ability to track and moni-
tor each participating beneficiary across clinical settings (such as home,
physician’s office, hospital). Operational capacity, record of achievement
in the provision of related services, and ability to absorb the financial
risk involved will also be considered in the process of soliciting and
evaluating bidding organizations.
The RFP instructs applicants to base their proposals on 20,000 beneficiaries
in the intervention group.35 Some health plans and smaller organizations
have expressed frustration that this requirement may thwart efforts to bring
these practices to rural areas because the geographic areas would need to
be quite large (for example, reaching across multiple states). Smaller orga-
nizations have raised concerns that such large geographic areas would
require them to manage a population that may be too large for them to
handle adequately. CMS has been encouraging smaller organizations to
form or join consortia to achieve CMS’s dual objectives of partnering with
a wide variety of organizations and testing scalability.
Some physician group practices have also expressed concern that they may
not be able to compete for these contracts. Unlike a prepaid group practice
model, the CCI approach allows participants to have complete freedom of
choice of physicians. Because the program is testing models that can im-
prove the quality of care and achieve savings with the FFS context, CMS
will not allow organizations to steer patients to certain physicians. This
freedom makes some physicians reluctant to be held accountable for the
outcomes of a predetermined group. Yet, in some areas, most notably Cali-
fornia, medical groups and independent practice associations take respon-
sibility for care management of their patient populations. A recent study
by Robin Gillies and colleagues found that California physician organiza-
tions are much more likely than their non-California counterparts to imple-
ment or use care management processes (such as disease registries, care
management, and feedback to physicians).36 Nevertheless, these physician
groups seem unlikely to be awarded (or even apply for) a contract, given
the size and population requirements of the program.
Some physician group
practices have ex-
pressed concern that
they may not be able
to compete for these
contracts.
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How Will the Regions Be Selected?
Related to the types of entities that will be permitted to participate is
the consideration of which geographic regions will be selected. The RFP
provides specific guidance on this issue.
CMS has determined that there will be approximately 10 pilot projects in
different regions around the country. Only one contractor will be selected for
any given geographic area. The RFP does not specify exact regions, but it
does make clear that size matters and that applications may be rejected if the
covered population is not big enough. Several factors will be given prefer-
ence in considering certain geographic areas (see Appendix):
■ Higher-than-average prevalence of CHF and/or diabetes or COPD
among FFS Medicare beneficiaries.
■ Poor Medicare quality rankings in comparison to national averages.
■ Areas that do not conflict with a currently operating FFS chronic
care demonstration.
CMS’s focus on prevalence and quality suggests a strategy to go where it can
get the most “bang for the buck.” This is consistent with a desire to achieve
results within three years. Providers located in high-quality markets fre-
quently complain that they cannot take advantage of these innovative
approaches and new Medicare dollars. On the other hand, given limited
resources, it might make more sense to go where the need is greatest.
In order to avoid cross-contamination of control groups, CMS decided not
to run a CCI program in the same geographic area where Medicare FFS
chronic care demonstrations are currently operating (see Appendix). This
determination excludes significant portions of the country from participat-
ing in the pilot project. In effect, it penalizes those areas that applied for
earlier demonstration projects, even if those efforts were on a much smaller
scale. However, CMS does encourage applicants who are interested in pro-
posing an area where a demonstration exists to contact CMS for details on
how such a proposal might be structured.37
How Important Is the Physician’s Role?
“Improving the quality of care ultimately requires changes in the behav-
ior of individual physicians,” according to a recent article by Arnold
Epstein, MD. and colleagues.38 Yet within the chronic care improvement
pilot project, the role of physicians is unclear. As Epstein asserts, many
quality experts believe strongly that the physician must play a central
role in order for care management strategies to be effective. Others argue
that strategies focused directly on patients taking responsibility for their
own care can be quite effective, with or without physician participation.
The answer probably lies somewhere in between.
Most current DM programs focus on the patients. Phone calls from and
access to trained staff (such as registered nurses), educational materials,
CMS decided not to
run a CCI program in
the same geographic
area where Medi-
care FFS chronic care
demonstrations are
currently operating.
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and individualized care management plans give patients the tools to
take better care of themselves.39 Some commercial programs have little
direct involvement with physicians, other than providing patients’
health status reports or reminders for follow-up care. Unless a sub-
stantial number of a physician’s patients are enrolled in a particular
program, it can be difficult to get physicians to respond to requests for
information, according to DM representatives. Many DM organiza-
tions have begun to promote “decision support” services to provid-
ers, such as patient registries and physician performance assessments,
to gain more physician collaboration.
Physicians, for their part, have reportedly had a mixed reaction to care
management tools. As characterized by cardiologist Janet Wright, MD,
DM organizations can be viewed as “interveners,” helpful to their prac-
tice, or as “interferers,” impinging on their professional autonomy.40
Some physicians view dollars paid to a DM company as money that
should have been paid directly to physicians. Robert Kolock, MD, re-
cently wrote “some doctors are annoyed when they are inundated by
what they perceive as useless or erroneous information.”41 On the other
hand, a recent study by the Center for Studying Health System Change
found that physicians generally believe care management tools, such as
practice guidelines, patient satisfaction surveys, and practice profiling
offered by some DM organizations, have a positive effect on the quality
and efficiency of care they provide.42
Proponents of greater physician involvement in this pilot project have
suggested that CCI programs could pay physicians through a subcapitated
arrangement. Individual doctors could therefore be rewarded for collabo-
rating with the care management plan (for example, reading and respond-
ing to CCI reports). Whereas payment might be one strategy, researchers
note that it is difficult to identify the main financial drivers that promote
physician involvement.
In the RFP, CMS expresses a particular interest in programs that have a
“track record of success in engaging beneficiaries’ physicians and other
providers for information sharing.”43 Applicants are required to dem-
onstrate “adequate mechanisms for ensuring physician integration with
the program.”44
Nevertheless, many experts agree that if the delivery system is truly to
move from its traditional acute-care emphasis toward one focused on
chronic care, physicians must be rewarded for doing so. This program
may not be the vehicle for that kind of systemic change. Its focus seems
to be on patients and self-management as change agents, rather than
physicians. Proponents of this approach seem content just to make a
difference where they can.
Many experts agree
that if the delivery sys-
tem is truly to move
from its traditional
acute-care emphasis
toward one focused on
chronic care, physicians
must be rewarded for
doing so.
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How Will CCI Programs Be
Integrated with Prescription Drug Plans?
The primary objective of the new Medicare law was to provide a pre-
scription drug benefit to Medicare beneficiaries. The new prescription
drug plans (PDPs)—intended to deliver the Medicare drug benefit to FFS
beneficiaries—are required to have in place “medication therapy man-
agement programs” to improve medication use and reduce the risk of
adverse events. The law specifically targets individuals with “multiple
chronic diseases (such as diabetes, asthma, hypertension, hyperlipidemia,
and [CHF])” as primary beneficiaries.
Historically, DM programs have also sought to reduce adverse reactions
and improve compliance with drug regimens. Pharmaceutical benefit man-
agement (PBM) firms have also played this role, but their emphasis has
been on reducing drug costs. DM programs, on the other hand, have some-
times been identified with increasing drug costs when enrollees are
encouraged to take specific medications as prescribed or when drugs are
substituted for more costly interventions in the later stages of a disease.
How these two approaches interact (or clash) in the marketplace may be a
critical determinant of the CCI program’s success. For example, diabetes
drugs are reportedly in the top five cost drivers for a PDP. The legislation
requires the DHHS secretary to establish guidelines for the coordination of
any medication therapy management plan with a CCI program. Aligning
these contradictory objectives may be easier said than done.
Moreover, the Medicare drug discount card (in June 2004) and Part D
pharmacy benefit (in January 2006) will be implemented during the
course of the three-year CCI study period. If participants in the pro-
gram and the control group enroll equally in these programs, then com-
parisons of the two groups should be valid. However, if one group
enrolls more than the other, cost accounting will be complicated. The
RFP specifies that Medicare drug expenditures will be included in the
calculation of total Medicare expenditures, beginning in 2006 when ben-
eficiaries will be given the opportunity to purchase Medicare prescrip-
tion drug benefits.
How Much Will Information
Technology Be Encouraged or Rewarded?
Throughout the Medicare legislation, there are incentives for investments
in information technology (IT). For example, the legislation establishes an
electronic prescribing program to be used by all physicians. It also extends
a program that rewards physicians’ offices with a monetary bonus if they
have certain IT systems (such as electronic medical records) in place.
Many quality experts have suggested that information technology can im-
prove care for patients with chronic conditions. Indeed, the IOM’s land-
mark quality report stated “[IT] must play a central role in the redesign of
DM programs have
sometimes been iden-
tified with increasing
drug costs when en-
rollees are encouraged
to take specific medica-
tions as prescribed.
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the health care system if a substantial improvement in quality is to be
achieved over the coming decade.”45
Some analysts have suggested that IT systems may ultimately replace
DM organizations by providing many of the same services (such as re-
minders about preventive visits or medications prescribed and/or drug
interaction information) directly to patients and physicians.46 A study
by Lawrence Casalino and colleagues found that clinical IT is signifi-
cantly associated with the use of care management processes (such as
clinical practice guidelines, physician feedback, and patient self-man-
agement training) by physician organizations.47
The extent to which the use of information technology will be encouraged
or rewarded under the new CCI program is not clear. The legislation sim-
ply requires CCI programs to “develop a clinical information database to
track and monitor each participant across settings.”48 The RFP recognizes
the potential of integrative information infrastructures and new applica-
tions of information and communication technologies. CMS solicits
applications from organizations that have proven to be successful in ap-
plying these tools to meet the needs of participants and their providers.
Thus, while sophisticated IT systems are not required, the pilot program
presents an important opportunity to test their effectiveness in improving
chronic care on a large scale. It might also encourage increased connectiv-
ity among regional providers and CCI programs (Figure 2).
FIGURE 2
Data Flow Envisioned by the New Chronic Care
Improvement Program Under the MMA of 2003
Based on a presentation by Sandra Foote, Director, Health Insurance Reform Project, at the American
Enterprise Institute on March 22, 2004.
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How Will CMS Measure Success?
The legislation requires that each CCI program be evaluated on the basis
of cost, quality, and patient satisfaction. However, some have expressed
concern that the legislation appears to have a definite formula for paying
for cost-savings results but not for quality. How much will cost concerns
outweigh quality in the evaluation of these programs?
Measuring cost effectiveness may prove difficult enough. Whereas some
commercial programs have demonstrated improved clinical perfor-
mance or patient outcomes, clear evidence of a consistent cost savings
is lacking. When cost effectiveness is shown, it is often difficult to deter-
mine which interventions caused the effect.49 The Congressional Bud-
get Office was skeptical enough about potential cost savings in the new
CCI program that it estimated its cost at $500 million over 10 years.
Though the program itself is mandated to be budget neutral, Congress
did provide start-up funding not to exceed $100 million (net of savings)
over three years to get the systems and the contracts up and running.
Because savings will be measured against expenditures in a random-
ized control group, the program does give a real opportunity to test
cost effectiveness.
Measurement of quality may prove even more problematic than costs.
The actual methodology is not defined in the legislation. CMS has identi-
fied a core set of clinical quality indicators, but the RFP specifies that
“detailed definitions of the indicators, measures, and calculation meth-
ods” will be agreed on between CMS and the individual contractors. As
problematic as it may be to achieve consensus on the metrics, the requi-
site data sources and manner in which they are collected may be even
more contentious. Assuring the comparability of the intervention and
control group can be extremely difficult. Some quality measurement ex-
perts have suggested that CMS should have a strong preference for mea-
sures that can be evaluated through existing administrative data wher-
ever possible, rather than requiring additional collection by CCI programs.
On the other hand, neither beneficiary satisfaction nor clinical outcomes
are available from Medicare claims data.
Questions have been raised about whether all of the programs will be
held accountable to the same standard or allowed to differ. With the
exception of a core set, standards appear to be allowed to vary across
CCI programs. As stated earlier, different interventions may make it
more difficult to prove effectiveness. Too much emphasis on the study
design, however, could stifle innovation and thwart the multidisciplinary
content of many of the successful programs.
For its part, CMS has indicated that the measurement standards will be
routine, transparent, and explicit. At the same time, however, CMS officials
have suggested that they would like “real time” ongoing evaluations to
allow them to make adjustments to increase chances of success.
Questions have been
raised about whether
all of the programs will
be held accountable to
the same standard or
allowed to differ.
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CONCLUSION
The new CCI pilot program clearly signals congressional intent to ex-
pand Medicare’s role in improving chronic care. Though many ques-
tions will need to be answered, the new program offers one of the first
opportunities for quality management within the FFS environment. The
extent to which this program might be leveraged to achieve more fun-
damental change is not yet apparent. Nonetheless, it will provide an
important test of the notion that improved chronic care management
will yield cost savings and improve quality and patient satisfaction for
Medicare beneficiaries.
This paper draws on insights gained from discussions with many national experts
on chronic care improvement in fee-for-service Medicare, including, in particu-
lar, those who participated in a meeting sponsored by the Health Insurance
Reform Project (HIRP) on January 26–27, 2004.
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DIABETES QUALITY
STATE FFS BENEFICIARIES (%) CHF (%) COPD (%)  RANK CONFLICTING DEMOS
AL 661,747 20 14 15 42 –––––
AK 45,728 9 6 6 33 –––––
AZ 474,227 12 9 10 29 AZ
AR 436,271 15 13 12 48 Northwestern AR
CA 2,557,305 7 5 5 44 CA
CO 339,159 12 11 12 7 CO
CT 454,662 18 12 12 9 South-central CT
DE 114,806 22 14 12 14 –––––
DC 73,382 11 7 4 37 DC
FL 2,240,227 18 12 15 41 Northern FL
GA 927,667 20 13 13 47 –––––
HI 116,160 2 2 1 16 –––––
ID 158,301 13 10 9 22 –––––
IL 1,535,043 17 13 11 46 Rural / Eastern IL
IN 854,548 19 14 14 27 Central / Western IN
IA 474,090 16 11 11 6 Northeastern IA, Northwestern IA
KS 371,539 15 12 11 30 –––––
KY 622,181 19 13 16 40 –––––
LA 543,327 20 15 12 51 Corridor I-49
ME 225,477 16 11 14 3 ME
MD 651,698 18 12 11 25 Montomery Co., DC Suburbs, Baltimore
MA 768,883 17 12 12 15 –––––
MI 1,376,774 22 14 14 26 MI
MN 596,098 14 10 8 10 Eastern rural MN, South-central MN
MS 430,625 19 13 11 50 –––––
MO 764,550 17 14 13 28 Southwestern MO, St. Louis
MT 142,428 11 10 11 13 Southeastern MT
NE 251,062 15 12 10 12 –––––
(continued)
APPENDIX
Factors Considered in Selecting Regions for Chronic Care Improvement Program
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DIABETES QUALITY
STATE FFS BENEFICIARIES (%) CHF (%) COPD (%)  RANK CONFLICTING DEMOS
NV 176,387 12 9 11 35 –––––
NH 176,330 16 11 12 1 Southwestern NH
NJ 1,089,135 21 16 13 43 –––––
NM 221,363 14 9 11 36 NM
NY 2,327,080 21 16 12 24 New York City
NC 1,141,084 20 12 12 23 Northwestern NC
ND 104,775 14 10 9 4 –––––
OH 1,497,640 20 15 14 38 –––––
OK 473,529 16 14 13 45 –––––
OR 336,477 10 7 7 11 –––––
PA 1,623,162 20 14 13 31 Eastern PA, Central Northeastern PA
RI 117,890 19 13 13 17 –––––
SC 597,582 22 13 12 32 –––––
SD 122,324 13 11 10 20 SD
TN 829,852 19 13 14 39 Northeastern TN
TX 2,112,410 19 14 12 49 Houston, Urban / Southern TX
UT 210,115 15 11 6 5 –––––
VT 92,798 15 10 11 2 Eastern VT
VA 914,745 19 12 11 18 Southwestern VA, Richmond
WA 616,018 13 10 9 19 West-central WA
WV 324,294 22 14 17 34 –––––
WI 769,142 16 11 9 8 North-central WI
WY 67,139 13 11 13 21 Northern WY
US Total 34,717,973 17 12 12 ––––– –––––
APPENDIX – Chronic Care Improvement Program  (continued)
Source: Federal Register, 69, no. 79 (April 23, 2004): 20068–20069.
